Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cannabis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    76 result(s) found for: Cannabis. Displaying page 3 of 4.
    « Previous 1  2  3  4  Next»
    EudraCT Number: 2014-001834-27 Sponsor Protocol Number: GWEP1415 Start Date*: 2015-01-14
    Sponsor Name:GW Research Ltd
    Full Title: An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes
    Medical condition: Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10073677 Severe myoclonic epilepsy of infancy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) PL (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-016065-29 Sponsor Protocol Number: GWCA0962 Start Date*: 2010-03-10
    Sponsor Name:GW Pharma Ltd.
    Full Title: A double blind, randomized, placebo-controlled, parallel group study of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in pa...
    Medical condition: Pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058019 Cancer pain PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) DE (Completed) PL (Completed) BG (Completed) HU (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-016529-32 Sponsor Protocol Number: GWCA0999 Start Date*: 2010-04-02
    Sponsor Name:GW Pharma Ltd
    Full Title: A multicenter, non-comparative, open-label extension study to assess the long term safety of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in patients with uncontrolled pers...
    Medical condition: Pain in patients with advanced cancer who experience inadequate analgesia during optimized chronic opioid therapy.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058019 Cancer pain PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) CZ (Completed) HU (Completed) DE (Completed) PL (Completed) LT (Completed) LV (Completed) EE (Prematurely Ended) BG (Completed) ES (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-004226-15 Sponsor Protocol Number: Can-Art1 Start Date*: 2018-10-26
    Sponsor Name:King Christian 10th Hospital for Rheumatology
    Full Title: CAN-ART The efficacy and safety of using cannabis derivatives cannabidiol (CBD) and tetrahydrocannabinol (THC) for the treatment of pain in patients with inflammatory arthritis (RA, AS). A rand...
    Medical condition: Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003208-19 Sponsor Protocol Number: GWID10160 Start Date*: 2011-11-16
    Sponsor Name:GW Pharma Ltd.
    Full Title: A randomised, double-blind, placebo-controlled parallel group, pilot study of GWP42003 in the symptomatic treatment of ulcerative colitis.
    Medical condition: Symptoms of diarrhoea, rectal bleeding, stool frequency and inflammation in subjects with ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-003771-18 Sponsor Protocol Number: GWSP08258 Start Date*: 2013-08-06
    Sponsor Name:GW Pharma Ltd.
    Full Title: The efficacy, safety and tolerability of Sativex as an adjunctive treatment to existing anti-spasticity medications in children aged 8 to 18 years with spasticity due to cerebral palsy or traumatic...
    Medical condition: Spasticity due to cerebral palsy (CP) or traumatic central nervous system injury.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10028335 Muscle spasticity PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-001140-61 Sponsor Protocol Number: GWDM1302 Start Date*: 2013-12-30
    Sponsor Name:GW Research Ltd.
    Full Title: A randomised, double blind, placebo controlled, parallel group, dose ranging study of GWP42004 as add on to metformin in the treatment of participants with Type 2 diabetes.
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016064-36 Sponsor Protocol Number: GWCA0958 Start Date*: 2010-03-10
    Sponsor Name:GW Pharma Ltd.
    Full Title: A double blind, randomized, placebo-controlled, parallel group study of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in p...
    Medical condition: Pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058019 Cancer pain PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) BE (Completed) GB (Completed) DE (Completed) RO (Completed) HU (Completed) EE (Prematurely Ended) LV (Completed) LT (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-000926-31 Sponsor Protocol Number: GWMS1137 Start Date*: 2011-06-29
    Sponsor Name:GW Pharma Ltd.
    Full Title: A Multicentre, Double-blind, Randomised Parallel Group, Placebo- controlled Study of the Effect of long-term treatment with Sativex on Cognitive Function and Mood of Patients with Spasticity due to...
    Medical condition: Spasticity in multiple sclerosis (MS).
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-002939-34 Sponsor Protocol Number: GWEP1424 Start Date*: 2014-12-29
    Sponsor Name:GW Research Ltd
    Full Title: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.
    Medical condition: Dravet syndrome
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10073677 Severe myoclonic epilepsy of infancy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-005453-21 Sponsor Protocol Number: BUPI02/05 Start Date*: 2006-03-01
    Sponsor Name:Laboratorios Inibsa S.A.
    Full Title: Bupivacaína en anestesia odontológica. Estudio comparativo, respecto a la articaína, de su eficacia clínica durante la extracción quirúrgica del tercer molar inferior incluido.
    Medical condition: Dolor en intervención odontológica
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001133-18 Sponsor Protocol Number: PH-2006-1 Start Date*: 2006-05-25
    Sponsor Name:Pharmos Corp.
    Full Title: CANNABINOR DENTAL IMPACTION PAIN STUDY PROOF-OF-CONCEPT DOSE-RANGING STUDY
    Medical condition: Cannabinor is as an analgesic and anti-inflammatory agent. By its nature, it has been designed to be more active at the CB2 peripheral receptors and have less activity at the central CB1 receptors....
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033371 Pain LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004247-30 Sponsor Protocol Number: THC-phMRI in patients Start Date*: 2008-09-09
    Sponsor Name:University Medical Center Utrecht
    Full Title: The Role of the Endocannabinoid System in Psychiatric Disorders and Symptoms: a Pharmacological fMRI study
    Medical condition: THis research project will be performed with patients with a psychiatric disorder in order to determine whether the endocannabinoid system is altered in psychiatric diseases. Psychistric disorders ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037175 Psychiatric disorders SOC
    9.1 10051623 Cannabinoids LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2007-001520-12 Sponsor Protocol Number: D1443C00013 Start Date*: 2008-01-11
    Sponsor Name:Unidade de Investigação em Saúde Mental e Psiquiatria do Centro Hospitalar Conde de Ferreira
    Full Title: Efficacy and distinctive effects of atypical antipsychotics on cognitive symptoms in dual diagnosis – A phase IIIb, randomized, open-labelled study to evaluate the cognitive effects of quetiapine X...
    Medical condition: Patients with both schizophrenia and substance abuse disorder
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004823-66 Sponsor Protocol Number: ELTCAN1 Start Date*: 2019-04-17
    Sponsor Name:Radboudumc
    Full Title: Early-life stress, the endocannabinoid system, and fear memory extinction
    Medical condition: healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10036876 Prolonged posttraumatic stress disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004094-17 Sponsor Protocol Number: 40-41200-98-9269 Start Date*: 2015-11-03
    Sponsor Name:Universiteit Utrecht
    Full Title: Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias.
    Medical condition: Phobic anxiety disorders: either generalized social phobia or panic disorder with agoraphobia.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10068299 Fear symptoms and phobic disorders (incl social phobia) HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2022-004238-20 Sponsor Protocol Number: CC21000 Start Date*: 2024-02-06
    Sponsor Name:Vejle Hospital
    Full Title: BONG: Breathlessness and alternatives to Opioid treatment in Non-malign Groups of severe lung disease
    Medical condition: COPD
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10075530 Medical cannabis therapy PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001965-36 Sponsor Protocol Number: FAAHIPTSD Start Date*: 2020-08-26
    Sponsor Name:Linkoping University
    Full Title: Effects of the FAAH inhibitor JNJ-42165279 in combination with internet-based cognitive behavioral therapy in PTSD
    Medical condition: post traumatic stress disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002372-36 Sponsor Protocol Number: 2022-16039 Start Date*: 2024-01-02
    Sponsor Name:Wageningen Research Stichting
    Full Title: The CanISleepinMS Study: Effect of cannabidiol (CBD) on sleep quality in patients with multiple sclerosis, a series of 15 randomised, placebo controlled N-of-1 trials
    Medical condition: Insomnia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022905-17 Sponsor Protocol Number: GWCA1103 Start Date*: 2011-12-26
    Sponsor Name:GW Pharma Ltd.
    Full Title: A two-part, placebo-controlled, study of the safety and efficacy of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in patien...
    Medical condition: Pain in patients with advanced cancer who have inadequate analgesia even with optimized chronic opioid therapy.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058019 Cancer pain PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) GB (Completed) LT (Completed) PL (Completed) DE (Completed) HU (Completed) RO (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 28 21:26:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA